246 related articles for article (PubMed ID: 34230073)
21. [(68)Ga-exendin-4 PET-CT for the localization of occult insulinomas: a prospective cohort study].
Luo YP; Pan QQ; Li F; Yu M; Xing XP; Zhang TP; Zhao YP
Zhonghua Wai Ke Za Zhi; 2018 Nov; 56(11):837-842. PubMed ID: 30392304
[No Abstract] [Full Text] [Related]
22.
Sakaki K; Murakami T; Fujimoto H; Shimizu Y; Miyake KK; Otani D; Kiyobayashi S; Okada T; Fujimoto M; Hakata T; Yamauchi I; Shimada K; Shimizu H; Nagai K; Nakamoto Y; Inagaki N
Front Endocrinol (Lausanne); 2023; 14():1245573. PubMed ID: 37720533
[TBL] [Abstract][Full Text] [Related]
23. [Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma.
Wicki A; Wild D; Storch D; Seemayer C; Gotthardt M; Behe M; Kneifel S; Mihatsch MJ; Reubi JC; Mäcke HR; Christofori G
Clin Cancer Res; 2007 Jun; 13(12):3696-705. PubMed ID: 17575235
[TBL] [Abstract][Full Text] [Related]
24. Glucagon-like peptide-1 receptor imaging for localization of insulinomas.
Christ E; Wild D; Forrer F; Brändle M; Sahli R; Clerici T; Gloor B; Martius F; Maecke H; Reubi JC
J Clin Endocrinol Metab; 2009 Nov; 94(11):4398-405. PubMed ID: 19820010
[TBL] [Abstract][Full Text] [Related]
25. Improving the Theranostic Potential of Exendin 4 by Reducing the Renal Radioactivity through Brush Border Membrane Enzyme-Mediated Degradation.
Zhang M; Jacobson O; Kiesewetter DO; Ma Y; Wang Z; Lang L; Tang L; Kang F; Deng H; Yang W; Niu G; Wang J; Chen X
Bioconjug Chem; 2019 Jun; 30(6):1745-1753. PubMed ID: 31181890
[TBL] [Abstract][Full Text] [Related]
26. Insulinoma imaging with glucagon-like peptide-1 receptor targeting probe (18)F-FBEM-Cys (39)-exendin-4.
Xu Y; Pan D; Xu Q; Zhu C; Wang L; Chen F; Yang R; Luo S; Yang M
J Cancer Res Clin Oncol; 2014 Sep; 140(9):1479-88. PubMed ID: 24838847
[TBL] [Abstract][Full Text] [Related]
27. Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study.
Christ E; Wild D; Ederer S; Béhé M; Nicolas G; Caplin ME; Brändle M; Clerici T; Fischli S; Stettler C; Ell PJ; Seufert J; Gloor B; Perren A; Reubi JC; Forrer F
Lancet Diabetes Endocrinol; 2013 Oct; 1(2):115-22. PubMed ID: 24622317
[TBL] [Abstract][Full Text] [Related]
28. Feasibility of a Scale-down Production of [
Migliari S; Sammartano A; Scarlattei M; Baldari G; Janota B; Bonadonna RC; Ruffini L
Curr Radiopharm; 2022; 15(1):63-75. PubMed ID: 33687908
[TBL] [Abstract][Full Text] [Related]
29. 64Cu- and 68Ga-labelled [Nle(14),Lys(40)(Ahx-NODAGA)NH2]-exendin-4 for pancreatic beta cell imaging in rats.
Mikkola K; Yim CB; Fagerholm V; Ishizu T; Elomaa VV; Rajander J; Jurttila J; Saanijoki T; Tolvanen T; Tirri M; Gourni E; Béhé M; Gotthardt M; Reubi JC; Mäcke H; Roivainen A; Solin O; Nuutila P
Mol Imaging Biol; 2014 Apr; 16(2):255-63. PubMed ID: 24101374
[TBL] [Abstract][Full Text] [Related]
30. Development of
Kimura H; Matsuda H; Ogawa Y; Fujimoto H; Toyoda K; Fujita N; Arimitsu K; Hamamatsu K; Yagi Y; Ono M; Inagaki N; Saji H
Bioorg Med Chem; 2017 Feb; 25(4):1406-1412. PubMed ID: 28089587
[TBL] [Abstract][Full Text] [Related]
31. Glucagon-like peptide-1 receptor imaging with [Lys40(Ahx-HYNIC- 99mTc/EDDA)NH2]-exendin-4 for the detection of insulinoma.
Sowa-Staszczak A; Pach D; Mikołajczak R; Mäcke H; Jabrocka-Hybel A; Stefańska A; Tomaszuk M; Janota B; Gilis-Januszewska A; Małecki M; Kamiński G; Kowalska A; Kulig J; Matyja A; Osuch C; Hubalewska-Dydejczyk A
Eur J Nucl Med Mol Imaging; 2013 Apr; 40(4):524-31. PubMed ID: 23224740
[TBL] [Abstract][Full Text] [Related]
32. Utility of
Kalff V; Iravani A; Akhurst T; Pattison DA; Eu P; Hofman MS; Hicks RJ
Intern Med J; 2021 Oct; 51(10):1657-1664. PubMed ID: 33314504
[TBL] [Abstract][Full Text] [Related]
33. Exendin-4 Derivatives with an Albumin-Binding Moiety Show Decreased Renal Retention and Improved GLP-1 Receptor Targeting.
Kaeppeli SAM; Jodal A; Gotthardt M; Schibli R; Béhé M
Mol Pharm; 2019 Sep; 16(9):3760-3769. PubMed ID: 31393738
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic challenges in a patient with an occult insulinoma:
Bongetti E; Lee MH; Pattison DA; Hicks RJ; Norris R; Sachithanandan N; MacIsaac RJ
Clin Case Rep; 2018 Apr; 6(4):719-722. PubMed ID: 29636947
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of Cu-64 and Ga-68 Radiolabeled Glucagon-Like Peptide-1 Receptor Agonists as PET Tracers for Pancreatic β cell Imaging.
Bandara N; Zheleznyak A; Cherukuri K; Griffith DA; Limberakis C; Tess DA; Jianqing C; Waterhouse R; Lapi SE
Mol Imaging Biol; 2016 Feb; 18(1):90-8. PubMed ID: 25987465
[TBL] [Abstract][Full Text] [Related]
36. Preliminary evaluation of [18F]AlF-NOTA-MAL-Cys39-exendin-4 in insulinoma with PET.
Xu Q; Zhu C; Xu Y; Pan D; Liu P; Yang R; Wang L; Chen F; Sun X; Luo S; Yang M
J Drug Target; 2015; 23(9):813-20. PubMed ID: 25758750
[TBL] [Abstract][Full Text] [Related]
37. Development of an
Iikuni S; Kamei I; Ohara T; Watanabe H; Ono M
Mol Pharm; 2022 Mar; 19(3):1019-1027. PubMed ID: 35138111
[TBL] [Abstract][Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
